FENC (Fennec Pharmaceuticals) Cyclically Adjusted Book per Share: $0.61 (As of Mar. 2026)


FENC Fennec Pharmaceuticals Inc FENC
54 GF Score
Price $11.02
GF Value $9.94
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Fennec Pharmaceuticals Cyclically Adjusted Book per Share?

Fennec Pharmaceuticals FENC +4.45% 54 Cyclically Adjusted Book per Share is $0.61 as of Mar. 2026. GuruFocus rates FENC with a GF Score™ of 54/100 and a GF Value™ of $9.94 (Modestly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Fennec Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was $1.091. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.61 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Fennec Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 9.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 5.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 10.30% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -0.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Fennec Pharmaceuticals was 41.90% per year. The lowest was -62.50% per year. And the median was -23.10% per year.

As of today (2026-06-26), Fennec Pharmaceuticals's current stock price is $11.02. Fennec Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $0.61. Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 18.07.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Fennec Pharmaceuticals was 23.75. The lowest was 7.43. And the median was 15.48.


Fennec Pharmaceuticals  (NAS:FENC) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=11.02/0.61
=18.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Fennec Pharmaceuticals was 23.75. The lowest was 7.43. And the median was 15.48.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Fennec Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Fennec Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Fennec Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fennec Pharmaceuticals Cyclically Adjusted Book per Share Chart

Fennec Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.48 0.52 0.53 0.56

Fennec Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.55 0.53 0.56 0.61

FENC vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fennec Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


FENC
54GF Score
Fennec Pharmaceuticals Inc FENC
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fennec Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Fennec Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.091/330.2130*330.2130
=1.091

Current CPI (Mar. 2026) = 330.2130.

Fennec Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.341 241.018 0.467
201609 0.309 241.428 0.423
201612 0.262 241.432 0.358
201703 0.210 243.801 0.284
201706 0.619 244.955 0.834
201709 0.559 246.819 0.748
201712 1.453 246.524 1.946
201803 1.388 249.554 1.837
201806 1.323 251.989 1.734
201809 1.197 252.439 1.566
201812 1.071 251.233 1.408
201903 0.965 254.202 1.254
201906 0.828 256.143 1.067
201909 0.754 256.759 0.970
201912 0.597 256.974 0.767
202003 0.425 258.115 0.544
202006 1.425 257.797 1.825
202009 1.208 260.280 1.533
202012 1.118 260.474 1.417
202103 0.959 264.877 1.196
202106 0.857 271.696 1.042
202109 0.731 274.310 0.880
202112 0.606 278.802 0.718
202203 0.481 287.504 0.552
202206 0.328 296.311 0.366
202209 0.107 296.808 0.119
202212 -0.097 296.797 -0.108
202303 -0.278 301.836 -0.304
202306 -0.367 305.109 -0.397
202309 -0.399 307.789 -0.428
202312 -0.430 306.746 -0.463
202403 0.111 312.332 0.117
202406 -0.050 314.175 -0.053
202409 -0.189 315.301 -0.198
202412 -0.213 315.605 -0.223
202503 -0.213 319.799 -0.220
202506 -0.269 322.561 -0.275
202509 -0.160 324.800 -0.163
202512 1.038 324.054 1.058
202603 1.091 330.213 1.091

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $0.61 mean?
Fennec Pharmaceuticals (FENC) has a Cyclically Adjusted Book per Share of $0.61 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Fennec Pharmaceuticals and its competitors.
Is Fennec Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Fennec Pharmaceuticals' current Cyclically Adjusted Book per Share is $0.61. Overall, Fennec Pharmaceuticals has a GF Score™ of 54/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fennec Pharmaceuticals' Cyclically Adjusted Book per Share compare to VRTX and REGN?
Fennec Pharmaceuticals' Cyclically Adjusted Book per Share of $0.61 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Fennec Pharmaceuticals and its competitors. Fennec Pharmaceuticals's current Cyclically Adjusted Book per Share is $0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fennec Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fennec Pharmaceuticals (FENC) is currently considered Modestly Overvalued. The stock's GF Value™ is $9.94, compared to a current price of $11.02 — trading 10.9% above its estimated fair value. The current Cyclically Adjusted Book per Share is $0.61. Fennec Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Fennec Pharmaceuticals (FENC), the current Cyclically Adjusted Book per Share is $0.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fennec Pharmaceuticals (FENC) Overvalued in 2026?

Based on GuruFocus' analysis, Fennec Pharmaceuticals stock appears to be overvalued. The current stock price of $11.02 is trading 10.9% above its estimated GF Value™ of $9.94. GuruFocus considers Fennec Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for FENC:

  • Cyclically Adjusted Book per Share: $0.61
  • GF Value™: $9.94 vs. price of $11.02 (10.9% above fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the FENC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fennec Pharmaceuticals Business Description

Other Exchanges RV41:GermanyFRX:Canada
Address 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
54GF Score

Get the complete analysis for FENC

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.02
Price
$9.94
GF Value